Advances in the treatment of neuromyelitis optic spectrum disorder

Advances in the treatment of neuromyelitis optic spectrum disorder

Blog Article

Neuromyelitis optic spectrum disorder (NMOSD) is a rare autoimmune disease characterized by Lanyards recurrent episodes and severe debilitation.It primarily involves the central nervous system and is associated with the presence of aquaporin-4 antibodies.Effective management of NMOSD necessitates long-term therapeutic strategies that focus on alleviating symptoms during acute episodes and preventing relapse.In recent years, the approval of emerging biologics targeting B cells, interleukin-6 receptors, and the complement pathway has marked a transformative development in NMOSD treatment.This article provides a comprehensive review of therapeutic advances in NMOSD, integrating Safety Shoes the current literature to serve as a theoretical basis for clinical decision-making of NMOSD patients.